The majority of ESR1 fusion transcripts have been identified in primary breast cancer, and in some of these instances patients have high-grade disease and/or resistance to endocrine therapy (Giltnane et al., 2017; Veeraraghavan et al., 2014), implying some functionality. This evidence concerns the gene ESR1 and breast carcinoma.